News

Patients on candesartan saw statistically significant reductions in the mean frequency of monthly headache days, including moderate to severe headache days.

When comparing galcanezumab, fremanezumab, and erenumab, 3 FDA-approved CGRP medications for preventive migraine, time to switch was lowest for erenumab and similar for galcanezumab and fremanezumab.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Ann Marie Morse, DO, FAAN. [LISTEN TIME: 20 minutes]

New data announced by Clene Nanomedicine suggested that the gold nanocrystal therapy reduced plasma neurofilament light chain, which principal investigator Merit Cudkowicz, MD, said, “help advance the design of a phase 3 trial.”

Investigators concluded that the increased prevalence of medication-overuse headache might be because of the lack of understanding about the condition in both providers and patients with migraine.

The chief of headache at UT Austin Dell Children’s Hospital provided insight on a new series designed to deliver longitudinal comprehensive pediatric headache education. [WATCH TIME: 3 minutes]

The assistant professor of occupational therapy at the New York Institute of Technology talked about educating patients with Parkinson disease about the importance of maintaining social participation for cognitive function at ATMRD 2023. [WATCH TIME: 5 minutes]

Findings from a subgroup analysis investigating kinetic oscillation stimulation showed that the treatment potential might be an effective and safe option for preventing chronic migraine.

The nurse practitioner in the movement disorder division at Georgetown University Hospital discussed differences in available therapies for movement disorders versus multiple sclerosis and using a chronic care management model in Parkinson disease. [WATCH TIME: 5 minutes]

Patients with Parkinson disease who were inpatients had significant impacts on their length of stay, readmissions, and morbidity after hospitalization when administered contraindicated medications.

Originally approved under the accelerated approval pathway, the promising efficacy observed in the study will prompt a future regulatory submission for traditional.

At AMTRD 2023, the graduate research assistant at Brown University talked about the prevalence of rapidly progressive dementia and cognition fluctuation in Parkinson disease as well as the effects of treatments for the condition. [WATCH TIME: 5 minutes]

Over a 39-day period, treatment with SCI-110 resulted an average reduction of 23% in agitation among patients with Alzheimer disease.

The professor of neurology at UMass Chan School of Medicine provided perspective on the benefits of pushing back school start times based on what research has shown.

Robert A. Hauser, MD, MBA, director of the Parkinson’s and Movement Disorders Center at the University of South Florida, provided insight on the therapeutic potential of IPX203, and why it adds flexibility to the treatment of Parkinson disease.

At AMTRD 2023, the movement disorder neurologist at the Parkinson’s Disease and Movement Disorder Center of Silicon Valley talked about the current care landscape for Parkinson disease and improving on-time for patients experiencing OFF periods. [WATCH TIME: 5 minutes]

In a recent survey, a group of advanced practice providers recognized the importance and considered the emotional impact of the unexpected return of symptoms on the life of a patient with Parkinson disease.

The nurse practitioner at the University of Southern California Keck Medical School provided insight on steps before deep brain stimulation and how they can impact outcomes for patients with Parkinson disease. [WATCH TIME: 4 minutes]

In a secondary analysis of a double-blind trial, mazindol extended-release outperformed placebo on clinician and patient scales of cataplexy severity and excessive daytime sleepiness.

Pooled results of a post hoc analysis from phase 3 studies of amantadine (Gocovri; Supernus) suggest that the therapy offers increased good ON time, and in intervals that are more predictable for patients, compared with placebo.

The assistant professor of neurology and director of the Movement Disorders Outreach Program at Mount Sinai Medical Center shed some light on the use of DBS in the clinic and how it has evolved as a therapeutic option for patients with Parkinson disease. [WATCH TIME: 2 minutes]

At CMSC 2023, the professor of psychiatry at the University of Toronto talked about cognitive behavioral therapy and mindfulness-based therapy that shows promise in alleviating fatigue in multiple sclerosis, offering potential treatment options. [WATCH TIME: 5 minutes]

Results from the phase 3 LAVENDER trial investigating trofinetide (Daybue; Acadia), which supported the first FDA-approved treatment for Rett syndrome, were recently published in Nature Medicine.

Here's some of what is coming soon to NeurologyLive® this week.

The executive director of the newly launched Association of Movement Disorder Advanced Practice Providers provided an overview of the organization and what it can offer to APPs. [WATCH TIME: 4 minutes]

Data from the phase 3 KINECT-HD study of valbenazine (Neurocrine Biosciences) provided a keen understanding of the threshold for clinically meaningful improvement in TMC scores. The VMAT2 inhibitor showed promising gains for patients.

At CMSC 2023, the Melissa and Paul Anderson President’s Distinguished Professor of Neurology at the Perelman School of Medicine of the University of Pennsylvania, talked about the phase 2 trials that show promising results for BTK inhibitors as a potential MS therapy. [WATCH TIME: 4 minutes]

The panel of movement disorder specialists and dermatologists offered a framework of suggestions for the supervision of the most common infusion-site reaction associated with these therapies.